Literature DB >> 25835348

Proton pump inhibitors and vascular function: A prospective cross-over pilot study.

Yohannes T Ghebremariam1, John P Cooke1, Fouzia Khan2, Rahul N Thakker2, Peter Chang2, Nigam H Shah2, Kevin T Nead2, Nicholas J Leeper3.   

Abstract

Proton pump inhibitors (PPIs) are commonly used drugs for the treatment of gastric reflux. Recent retrospective cohorts and large database studies have raised concern that the use of PPIs is associated with increased cardiovascular (CV) risk. However, there is no prospective clinical study evaluating whether the use of PPIs directly causes CV harm. We conducted a controlled, open-label, cross-over pilot study among 21 adults aged 18 and older who are healthy (n=11) or have established clinical cardiovascular disease (n=10). Study subjects were assigned to receive a PPI (Prevacid; 30 mg) or a placebo pill once daily for 4 weeks. After a 2-week washout period, participants were crossed over to receive the alternate treatment for the ensuing 4 weeks. Subjects underwent evaluation of vascular function (by the EndoPAT technique) and had plasma levels of asymmetric dimethylarginine (ADMA, an endogenous inhibitor of endothelial function previously implicated in PPI-mediated risk) measured prior to and after each treatment interval. We observed a marginal inverse correlation between the EndoPAT score and plasma levels of ADMA (r = -0.364). Subjects experienced a greater worsening in plasma ADMA levels while on PPI than on placebo, and this trend was more pronounced amongst those subjects with a history of vascular disease. However, these trends did not reach statistical significance, and PPI use was also not associated with an impairment in flow-mediated vasodilation during the course of this study. In conclusion, in this open-label, cross-over pilot study conducted among healthy subjects and coronary disease patients, PPI use did not significantly influence vascular endothelial function. Larger, long-term and blinded trials are needed to mechanistically explain the correlation between PPI use and adverse clinical outcomes, which has recently been reported in retrospective cohort studies.
© The Author(s) 2015.

Entities:  

Keywords:  asymmetric dimethylarginine; cardiovascular risk factors; dimethylarginine dimethylaminohydrolase; nitric oxide; proton pump inhibitors

Mesh:

Substances:

Year:  2015        PMID: 25835348      PMCID: PMC4572842          DOI: 10.1177/1358863X14568444

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  39 in total

Review 1.  Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors.

Authors:  C A Stedman; M L Barclay
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

2.  The value of branded proton pump inhibitors: formulary considerations.

Authors:  David A Peura; Rosemary R Berardi; Javier Gonzalez; Louis Brunetti
Journal:  P T       Date:  2011-07

Review 3.  Asymmetrical dimethylarginine: the Uber marker?

Authors:  John P Cooke
Journal:  Circulation       Date:  2004-04-20       Impact factor: 29.690

Review 4.  Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction.

Authors:  Billie-Jean Martin; Todd J Anderson
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

Review 5.  Pharmacological management of GERD: where does it stand now?

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  Trends Pharmacol Sci       Date:  2011-03-22       Impact factor: 14.819

6.  Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population.

Authors:  P Wanby; T Teerlink; L Brudin; L Brattström; I Nilsson; P Palmqvist; M Carlsson
Journal:  Atherosclerosis       Date:  2005-08-01       Impact factor: 5.162

7.  Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

Authors:  R H Böger; S M Bode-Böger; A Szuba; P S Tsao; J R Chan; O Tangphao; T F Blaschke; J P Cooke
Journal:  Circulation       Date:  1998-11-03       Impact factor: 29.690

8.  Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.

Authors:  Rainer H Böger; Lisa M Sullivan; Edzard Schwedhelm; Thomas J Wang; Renke Maas; Emelia J Benjamin; Friedrich Schulze; Vanessa Xanthakis; Ralf A Benndorf; Ramachandran S Vasan
Journal:  Circulation       Date:  2009-03-16       Impact factor: 29.690

9.  Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.

Authors:  C Cederberg; A B Thomson; V Mahachai; J A Westin; P Kirdeikis; D Fisher; L Zuk; B Marriage
Journal:  Gastroenterology       Date:  1992-09       Impact factor: 22.682

10.  Evaluation of the EndoPAT as a Tool to Assess Endothelial Function.

Authors:  M Moerland; A J Kales; L Schrier; M G J van Dongen; D Bradnock; J Burggraaf
Journal:  Int J Vasc Med       Date:  2012-02-14
View more
  15 in total

Review 1.  Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.

Authors:  Felice Schnoll-Sussman; Philip O Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

2.  Proton Pump Inhibitors Accelerate Endothelial Senescence.

Authors:  Gautham Yepuri; Roman Sukhovershin; Timo Z Nazari-Shafti; Michael Petrascheck; Yohannes T Ghebre; John P Cooke
Journal:  Circ Res       Date:  2016-05-10       Impact factor: 17.367

Review 3.  Proton-pump inhibitors: understanding the complications and risks.

Authors:  Peter Malfertheiner; Arne Kandulski; Marino Venerito
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

4.  Proton-Pump Inhibitor Use and the Risk of First-Time Ischemic Stroke in the General Population: A Nationwide Population-Based Study.

Authors:  Yen-Feng Wang; Yung-Tai Chen; Jiing-Chyuan Luo; Tzeng-Ji Chen; Jaw-Ching Wu; Shuu-Jiun Wang
Journal:  Am J Gastroenterol       Date:  2017-04-11       Impact factor: 10.864

5.  Can Endothelial Injury Provide the Passage to Explain the Vascular Effects of Proton Pump Inhibitors?

Authors:  Surovi Hazarika; Brian H Annex
Journal:  Circ Res       Date:  2016-06-10       Impact factor: 17.367

Review 6.  How May Proton Pump Inhibitors Impair Cardiovascular Health?

Authors:  Roman A Sukhovershin; John P Cooke
Journal:  Am J Cardiovasc Drugs       Date:  2016-06       Impact factor: 3.571

Review 7.  Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.

Authors:  Joseph Mermelstein; Alanna Chait Mermelstein; Maxwell M Chait
Journal:  Clin Exp Gastroenterol       Date:  2016-07-13

8.  Asymmetric Dimethylarginine versus Proton Pump Inhibitors Usage in Patients with Stable Coronary Artery Disease: A Cross-Sectional Study.

Authors:  Olga Kruszelnicka; Jolanta Świerszcz; Jacek Bednarek; Bernadeta Chyrchel; Andrzej Surdacki; Jadwiga Nessler
Journal:  Int J Mol Sci       Date:  2016-04-15       Impact factor: 5.923

9.  Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction.

Authors:  Lucas C Pinheiro; Gustavo H Oliveira-Paula; Rafael L Portella; Danielle A Guimarães; Celio D de Angelis; Jose E Tanus-Santos
Journal:  Redox Biol       Date:  2016-08-04       Impact factor: 11.799

Review 10.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.